Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 2Pancreatic Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 9Daunorubicin 7Etoposide 6Methotrexate 5Idarubicin 5Thioguanine 4Mitoxantrone 4Cyclophosphamide 4Hydrocortisone 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Asparaginase 3Tacrolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2ON 01910 2Mycophenolic Acid 2Dexamethasone 2Busulfan 2zosuquidar trihydrochloride 1valspodar 1tipifarnib 1sargramostim 1palmitoyl-L-asparaginase 1merphos 1lonafarnib 1hydrocortisone hemisuccinate 1fludarabine phosphate 1fludarabine 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anemia, Refractory, with Excess of Blasts × tipifarnib × Clear all
NCT00093470 2024-03-20

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

National Cancer Institute (NCI)

Phase 3 Completed
144 enrolled 8 charts
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡